- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03078101
EMPRA (EMPagliflozin and RAs in Kidney Disease) (EMPRA)
Effect of Empagliflozin on the Renin-angiotensin System in Patients With Chronic
This study will be a prospective, clinical pilot study in CKD patients to show whether Empagliflozin in addition to ACEi treatment significantly increases Ang 1-7 levels compared to ACEi treatment alone.
Null and alternative hypotheses:
H0: Empagliflozin in addition to ACEi treatment does not increase Ang 1-7 levels more than ACEi treatment alone.
H1: Empagliflozin in addition to ACEi treatment significantly increases Ang 1-7 levels compared to ACEi treatment alone
Methodology:
Two groups of 24 chronic kidney disease (CKD) patients, respectively, with and without type 2 diabetes will be randomized into the study medication or placebo group. The number of patients per treatment arms is n = 12. Included and consented patients will be subjected to an initial 2-week run-in period for conversion of current RAS blocking medications to ACEi therapy with enalapril or ramipril and respective dose titration to 10 mg enalapril 2 x daily and 10 mg ramipril 1 x daily. Additional antihypertensive medication will be standardized as feasible, with the primary goal of keeping blood pressure as recommended by KDIGO. Following the 2-week run-in phase, all study patients will be subjected to blood collection including the first RAS quantification (RAS Fingerprint) and assessment of HDL composition, as well as urinary analysis and bioimpedance fluid status assessment (BCM measurement). Subsequently, patients will be randomized to either receive empagliflozin (at a dose of 10 mg daily) or placebo. Subsequently, biweekly study visits including electrolyte and glucose (plasma and urine) monitoring as well as BCM measurement will take place. After 12 weeks of study medication intake, a concluding study visit will be scheduled for final RAS quantification (RAS Fingerprint) and HDL analyses as well as final blood and urinary analysis and BCM measurement. Initially, blood and urine will be collected at the clinical visit as part of the routine blood obtainment (no additional effort on patients). From these routine measurements we will be able to extract information regarding the patient's current CKD stage as well as other relevant laboratory parameters (e.g. HbA1c, UACR, etc.). Furthermore, we will document the patient's current medication and significant comorbidities.
Primary analysis variable/endpoint:
The difference of Ang 1-7 increase from baseline between a 3-month treatment with empagliflozin on top of ACEi treatment compared to ACEi treatment alone
Most important secondary analysis variables/endpoints:
- Simultaneous quantitative changes of multiple RAS effector angiotensin levels determined by mass-spectrometry
- Recurrence of Ang II levels determined by mass-spectrometry
- HDL parameters (protein composition of HDL)
- Renal parameters (albuminuria reduction measured by urinary albumin-creatinine ratio (UACR), renal function (estimated glomerular filtration rate (GFR), serum-creatinine)
- Urinary electrolyte levels
- Urinary glucose levels
- Urinary RAS metabolites (angiotensinogen, ACE and ACE2 levels, ACE2 activity)
- Blood pressure determined by ambulatory blood pressure measurements
- Body volume determined by bioimpedance fluid status assessment (BCM measurement)
- OCR and ECAR in PBMCs determined by Seahorse Flux Analyzer
- Assessment of reduction of salt sensitivity by using salt sensitivity test with empagliflozin
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Vienna, Austria, 1090
- Department of Internal Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Austria
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
for CKD patients with type 2 diabetes
- Estimated GFR (calculated with the MDRD-IDMS formula) between 15 and 59 ml/min (with CKD stage IIIa/b to IV)
- Albumin excretion rates of 30-300 mg/24 hours (UACR <300 mg/g)
- Fasting plasma glucose levels >126 mg/dl [7mmol/L] or HbA1c levels >6.5% (Definition of type 2 diabetes according to the diagnostic criteria set forth by the American Diabetes Association in 2009)
for CKD patients without Diabetes
- Estimated GFR (calculated with the MDRD-IDMS formula) between 15 and 59 ml/min (with CKD stage IIIa/b to IV)
- Albumin excretion rates of 30-300 mg/24 hours (UACR <300 mg/g)
Exclusion Criteria:
CKD patients with type 2 diabetes
- Age <18 years
- Severely impaired renal function (eGFR <15ml/min)
- Hyperkalemia above 4.5mmol/L
- Hypotension (systolic blood pressure lower than 120 mmHg on ambulatory measurement)
- Pregnant patients
- Patients planning pregnancy
- Body mass index < 18.5 kg/m2
for CKD patients without diabetes
- Age <18 years
- Diabetic kidney disease
- Severely impaired renal function (eGFR <15ml/min)
- Hypotension (systolic blood pressure lower than 120 mmHg on ambulatory measurement)
- Pregnant patients
- Patients planning pregnancy
- Body mass index < 18.5 kg/m2 -
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Group A
Diabetic CKD patients receiving Empagliflozin 10 MG [Jardiance]
|
administered orally once daily
|
PLACEBO_COMPARATOR: Group B
Diabetic CKD patients receiving Placebo Oral Tablet
|
administered orally once daily
|
EXPERIMENTAL: Group C
Non-diabetic CKD patients receiving Empagliflozin 10 MG [Jardiance]
|
administered orally once daily
|
PLACEBO_COMPARATOR: Group D
Non-diabetic CKD patients receiving 'Placebo Oral Tablet
|
administered orally once daily
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The difference of Ang 1-7 increase from baseline between a 3-month treatment with empagliflozin on top of ACEi treatment compared to ACEi treatment alone
Time Frame: Visit 2 and Visit 8; 3 months
|
The difference of Ang 1-7 increase from baseline between a 3-month treatment with empagliflozin on top of ACEi treatment compared to ACEi treatment alone
|
Visit 2 and Visit 8; 3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean quantitative changes of baseline multiple RAS effector angiotensin levels after 3 months of empagaliflozin treatment
Time Frame: Visit 2 and Visit 8; 3 months
|
Mean quantitative changes of baseline multiple RAS effector angiotensin levels after 3 months of empagaliflozin treatment
|
Visit 2 and Visit 8; 3 months
|
Mean changes of baseline Ang II levels after 3 months of empagaliflozin treatment
Time Frame: Visit 2 and Visit 8; : 3 months
|
Mean changes of baseline Ang II levels after 3 months of empagaliflozin treatment
|
Visit 2 and Visit 8; : 3 months
|
Mean changes of baseline specific protein amount on HDL after 3 months of empagaliflozin treatment
Time Frame: Visit 2 and Visit 8; 3 months
|
Mean changes of baseline specific protein amount on HDL after 3 months of empagaliflozin treatment
|
Visit 2 and Visit 8; 3 months
|
Mean changes in specific renal parameters from baseline in 3 months of empagaliflozin treatment (albuminuria reduction, renal function)
Time Frame: Visit 2 ,3,4,5,6,7,8; 3 months
|
Mean changes in specific renal parameters from baseline in 3 months of empagaliflozin treatment (albuminuria reduction, renal function)
|
Visit 2 ,3,4,5,6,7,8; 3 months
|
Mean changes from baseline relevant blood parameters (HbA1c, β-hydroxybutyrat, elektrolytes, lipids, etc.) after 3 months of empagaliflozin treatment
Time Frame: Visit 2 ,3,4,5,6,7,8; 3 months
|
Mean changes from baseline relevant blood parameters (HbA1c, β-hydroxybutyrat, elektrolytes, lipids, etc.) after 3 months of empagaliflozin treatment
|
Visit 2 ,3,4,5,6,7,8; 3 months
|
Mean changes from baseline urinary RAS metabolites (angiotensinogen, ACE and ACE2 levels, ACE2 activity) after 3 months of empagaliflozin treatment
Time Frame: Visit 2 and Visit 8; 3 months
|
Mean changes from baseline urinary RAS metabolites (angiotensinogen, ACE and ACE2 levels, ACE2 activity) after 3 months of empagaliflozin treatment
|
Visit 2 and Visit 8; 3 months
|
Mean changes in baseline blood pressure after 3 months of empagaliflozin treatment
Time Frame: Visit 2 ,3,4,5,6,7,8; 3 months
|
Mean changes in baseline blood pressure after 3 months of empagaliflozin treatment
|
Visit 2 ,3,4,5,6,7,8; 3 months
|
Mean changes in body fluid status after 3 months of empagaliflozin treatment
Time Frame: Visit 2 and Visit 8; 3 months
|
Mean changes in body fluid status after 3 months of empagaliflozin treatment
|
Visit 2 and Visit 8; 3 months
|
Mean changes in baseline oxygen consumption rate (OCR) and the extracellular acidification rate (ECAR) in peripheral peripheral blood mononuclear cells (PBMCs) after 3 months of empagliflozin treatment
Time Frame: Visit 2 and Visit 8; 3 months
|
Mean changes in baseline oxygen consumption rate (OCR) and the extracellular acidification rate (ECAR) in peripheral peripheral blood mononuclear cells (PBMCs) after 3 months of empagliflozin treatment
|
Visit 2 and Visit 8; 3 months
|
Mean changes in salt sensitivity after 3 months of empagliflozin treatment
Time Frame: Visit 2 and Visit 8; 3 months
|
Mean changes in salt sensitivity after 3 months of empagliflozin treatment
|
Visit 2 and Visit 8; 3 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of symptomatic hypoglycemia and confirmed hypoglycemic events (plasma glucose level ≤70 mg/dl or an event requiring assistance)
Time Frame: Visit 2 ,3,4,5,6,7,8; timeframe: 3 months
|
Number of symptomatic hypoglycemia and confirmed hypoglycemic events (plasma glucose level ≤70 mg/dl or an event requiring assistance)
|
Visit 2 ,3,4,5,6,7,8; timeframe: 3 months
|
Number of adverse events reflecting urinary tract infections, genital infections, volume depletion, acute renal failure, bone fractures, diabetic ketoacidosis and thromboembolic events.
Time Frame: Visit 2 ,3,4,5,6,7,8; 3 months
|
Number of adverse events reflecting urinary tract infections, genital infections, volume depletion, acute renal failure, bone fractures, diabetic ketoacidosis and thromboembolic events.
|
Visit 2 ,3,4,5,6,7,8; 3 months
|
Number of cardiovascular events (i.e. stroke, myocardial infarction, heart failure) during the study.
Time Frame: Visit 2 ,3,4,5,6,7,8; 3 months
|
Number of cardiovascular events (i.e.
stroke, myocardial infarction, heart failure) during the study.
|
Visit 2 ,3,4,5,6,7,8; 3 months
|
Number of hospitalizations during the study.
Time Frame: Visit 2 ,3,4,5,6,7,8; 3 months
|
Number of hospitalizations during the study.
|
Visit 2 ,3,4,5,6,7,8; 3 months
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Urologic Diseases
- Endocrine System Diseases
- Diabetes Complications
- Diabetes Mellitus
- Renal Insufficiency
- Diabetes Mellitus, Type 2
- Kidney Diseases
- Renal Insufficiency, Chronic
- Diabetic Nephropathies
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Sodium-Glucose Transporter 2 Inhibitors
- Empagliflozin
Other Study ID Numbers
- EUDRACT-Nr: 2016-002935-14
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
AstraZenecaRecruiting
Clinical Trials on Empagliflozin 10 MG [Jardiance]
-
Instituto Nacional de Cardiologia Ignacio ChavezNot yet recruitingSTEMI | No-Reflow Phenomenon
-
Damanhour UniversityRecruitingHeart Failure | Reduced Ejection Fraction Heart FailureEgypt
-
University of Mississippi Medical CenterEli Lilly and CompanyRecruiting
-
Ain Shams UniversityDrug Research Centre, Cairo, EgyptCompletedDiabetes Mellitus | Pharmacokinetics | PharmacodynamicsEgypt
-
Medical University of ViennaCompletedPosttransplant Diabetes MellitusAustria
-
Mario Negri Institute for Pharmacological ResearchBoehringer IngelheimWithdrawnObesity | Non-diabetic Chronic Kidney Disease
-
NYU Langone HealthNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Boehringer...Recruiting
-
Pharma NuevaNot yet recruiting
-
Anita SarafThe Pittsburgh FoundationNot yet recruitingHeart Failure | Adult Congenital Heart DiseaseUnited States
-
Maria Sklodowska-Curie National Research Institute...Medical Research Agency, PolandRecruiting